Sygnis Pharma AG

https://www.sygnis.de

SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). According to the 2012 newly defined business strategy, the company focuses on the development and marketing of novel technologies in molecular biology, e.g. in the field of DNA amplification and sequencing. For the key product "Qualiphi®", an improved polymerase for amplifying DNA, an exclusive worldwide license has been granted to Qiagen in July 2012. *

	Start	2008-06-09 existent
	Group	2invest (Group)
	Today	Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
	Successor	Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
	Industry	drug discovery
	Person	de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)

	Region	Heidelberg
	Country	Germany
	Street	515 Im Neuenheimer Feld
	City	69120 Heidelberg
	Tel	+49-62214546
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	200,000 (revenues, mainly X-Pol (2012) 2012-12-31)
	Profit	-2,400,000 (2012-12-31)
	Cash	500,000 (2012-12-31)

		* Document for »About Section«:

		Record changed: 2024-12-29

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for 2invest (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)